Published in Nat Rev Drug Discov on March 01, 2010
An atlas of genetic influences on human blood metabolites. Nat Genet (2014) 3.21
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature (2015) 2.01
A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet (2015) 1.98
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov (2013) 1.78
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2011) 1.77
Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov (2010) 1.73
Benchmarking membrane protein detergent stability for improving throughput of high-resolution X-ray structures. Structure (2011) 1.62
Crystal structure of a eukaryotic phosphate transporter. Nature (2013) 1.60
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs (2013) 1.49
Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. Xenobiotica (2012) 1.44
Accurate Prediction of Ligand Affinities for a Proton-Dependent Oligopeptide Transporter. Cell Chem Biol (2016) 1.42
What do drug transporters really do? Nat Rev Drug Discov (2014) 1.41
Na⁺/H⁺ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney. J Am Soc Nephrol (2014) 1.41
The determination and interpretation of the therapeutic index in drug development. Nat Rev Drug Discov (2012) 1.40
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes (2012) 1.38
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35
Sex differences in drug disposition. J Biomed Biotechnol (2011) 1.33
Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther (2011) 1.33
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem (2011) 1.30
Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help? CPT Pharmacometrics Syst Pharmacol (2016) 1.29
Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A (2011) 1.29
Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos (2011) 1.24
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A (2014) 1.24
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos (2013) 1.18
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem (2012) 1.18
Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. PLoS One (2011) 1.17
An integrated pharmacokinetics ontology and corpus for text mining. BMC Bioinformatics (2013) 1.17
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res (2012) 1.15
Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther (2011) 1.14
The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transport. Br J Pharmacol (2011) 1.13
The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. Br J Pharmacol (2011) 1.13
The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med (2013) 1.12
The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol (2014) 1.11
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med (2013) 1.11
Structural basis for polyspecificity in the POT family of proton-coupled oligopeptide transporters. EMBO Rep (2014) 1.10
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem (2013) 1.10
The blood-brain barrier: an engineering perspective. Front Neuroeng (2013) 1.09
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol (2011) 1.09
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother (2012) 1.08
Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health B Crit Rev (2013) 1.06
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res (2010) 1.06
Coordinating the impact of structural genomics on the human α-helical transmembrane proteome. Nat Struct Mol Biol (2013) 1.05
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med (2011) 1.05
Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J (2013) 1.04
Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov Today (2013) 1.03
Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. J Med Chem (2012) 1.03
Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol (2013) 1.03
Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics. AAPS J (2014) 1.03
Non-systemic drugs: a critical review. Curr Pharm Des (2012) 1.02
The UCSF-FDA TransPortal: a public drug transporter database. Clin Pharmacol Ther (2012) 1.02
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res (2012) 1.02
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin Pharmacol Ther (2013) 1.02
SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov (2015) 1.02
OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics (2013) 1.02
In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res (2011) 1.01
Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters. PLoS One (2011) 1.01
The organic anion transporter (OAT) family: a systems biology perspective. Physiol Rev (2015) 1.01
A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther (2012) 1.00
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 1.00
Pharmacogenomics of human ABC transporter ABCC11 (MRP8): potential risk of breast cancer and chemotherapy failure. Anticancer Agents Med Chem (2010) 0.99
Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods (2010) 0.99
Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Pharmacology (2012) 0.99
Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One (2011) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J (2012) 0.98
Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research. AIDS Res Hum Retroviruses (2013) 0.98
Annotating Human P-Glycoprotein Bioassay Data. Mol Inform (2012) 0.98
Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther (2011) 0.98
Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity. PLoS One (2013) 0.98
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch (2013) 0.97
Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm (2015) 0.96
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos (2013) 0.96
Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein. Acta Crystallogr D Biol Crystallogr (2015) 0.96
Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health. Front Chem (2014) 0.96
Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos (2012) 0.95
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol (2012) 0.95
A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet (2014) 0.95
Molecular modeling and ligand docking for solute carrier (SLC) transporters. Curr Top Med Chem (2013) 0.95
The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS (2013) 0.95
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet (2013) 0.95
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol (2014) 0.95
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos (2010) 0.94
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol (2015) 0.93
Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos (2011) 0.92
Apple juice greatly reduces systemic exposure to atenolol. Br J Clin Pharmacol (2013) 0.92
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol (2015) 0.92
Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos (2013) 0.92
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol (2011) 0.91
Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters. Clin J Am Soc Nephrol (2015) 0.91
Multilayer spheroids to quantify drug uptake and diffusion in 3D. Mol Pharm (2014) 0.91
Rationale for further medical and health research on high-potency sweeteners. Chem Senses (2012) 0.91
Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol (2012) 0.90
Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs. CPT Pharmacometrics Syst Pharmacol (2013) 0.90
Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol Psychiatry (2013) 0.90
In silico analysis of the conservation of human toxicity and endocrine disruption targets in aquatic species. Environ Sci Technol (2014) 0.90
Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat (2012) 0.90
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12.09
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (2009) 8.65
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch (2003) 3.76
Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res (2007) 3.72
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev (2003) 3.69
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther (2005) 3.26
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol (2002) 2.90
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 2.83
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (2007) 2.80
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta (2003) 2.53
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem (2001) 2.42
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology (2001) 2.36
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther (2005) 2.35
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog (1995) 2.25
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet (1999) 2.24
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol (2000) 2.21
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica (2008) 2.18
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther (1997) 2.17
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem (2005) 2.07
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos (2007) 1.97
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 1.96
P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm (2006) 1.95
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther (2007) 1.90
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem (1999) 1.87
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev (2008) 1.83
Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol (2001) 1.83
Digoxin-quinidine interaction Pharmacokinetic evaluation. N Engl J Med (1979) 1.82
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev (1998) 1.76
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther (2005) 1.74
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther (2005) 1.74
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther (2003) 1.74
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet (2001) 1.72
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther (2004) 1.68
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther (2004) 1.67
Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res (1993) 1.65
ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol (2008) 1.65
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica (2008) 1.64
In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos (2007) 1.63
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol (2005) 1.62
Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther (2000) 1.60
Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet (1987) 1.58
Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther (2008) 1.57
Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol (2006) 1.56
Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res (2007) 1.55
Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci (2006) 1.52
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther (2004) 1.51
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics (2008) 1.50
Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther (2008) 1.50
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther (2006) 1.48
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos (2007) 1.47
Global analysis of genetic variation in SLCO1B1. Pharmacogenomics (2008) 1.47
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics (2009) 1.46
Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol (1994) 1.46
The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res (2009) 1.46
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos (2007) 1.46
Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol (1999) 1.45
Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol (2003) 1.45
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther (2006) 1.45
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 1.43
Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol (2006) 1.43
Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica (2008) 1.40
Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev (2008) 1.39
Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J Biol Chem (2008) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther (2005) 1.35
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta (2006) 1.34
Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther (2008) 1.34
Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes (2009) 1.34
Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol (2005) 1.33
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem (2008) 1.32
Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet (2006) 1.31
Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol (2005) 1.30
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol (1987) 1.29
Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics (2004) 1.28
The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol (2006) 1.28
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther (2006) 1.27
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A (2004) 1.27
Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos (2006) 1.26
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther (1995) 1.25
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos (2008) 1.24
A TALE nuclease architecture for efficient genome editing. Nat Biotechnol (2010) 26.47
Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res (2009) 15.15
Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol (2008) 14.20
Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 12.40
Knockout rats via embryo microinjection of zinc-finger nucleases. Science (2009) 12.33
Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol (2011) 11.76
Targeted genome editing across species using ZFNs and TALENs. Science (2011) 9.84
Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol (2011) 8.45
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
A map of rice genome variation reveals the origin of cultivated rice. Nature (2012) 4.92
Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature (2009) 4.71
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
A review of electrode materials for electrochemical supercapacitors. Chem Soc Rev (2011) 3.88
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Analyses and comparison of accuracy of different genotype imputation methods. PLoS One (2008) 3.41
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos (2003) 3.33
Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction? Am J Psychiatry (2007) 3.33
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. Hum Mol Genet (2008) 3.24
Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nat Genet (2002) 3.06
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther (2006) 2.83
EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer (2010) 2.81
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81
Rapid and efficient clathrin-mediated endocytosis revealed in genome-edited mammalian cells. Nat Cell Biol (2011) 2.79
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. Proc Natl Acad Sci U S A (2011) 2.61
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res (2003) 2.47
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology (2006) 2.43
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Targeted transgene integration in plant cells using designed zinc finger nucleases. Plant Mol Biol (2008) 2.40
Genome-wide analysis of epigenetic signatures for kidney-specific transporters. Kidney Int (2010) 2.39
Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev (2007) 2.38
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut (2011) 2.38
Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation (2007) 2.38
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res (2011) 2.30
A SNP in the ABCC11 gene is the determinant of human earwax type. Nat Genet (2006) 2.29
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol (2008) 2.23
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. PLoS Genet (2011) 2.22
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther (2002) 2.21
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Identification of chromosome sequence motifs that mediate meiotic pairing and synapsis in C. elegans. Nat Cell Biol (2009) 2.15
A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev Cell (2006) 2.13
FSIM: a feature similarity index for image quality assessment. IEEE Trans Image Process (2011) 2.13
Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med (2002) 2.13
Low-dose X-ray CT reconstruction via dictionary learning. IEEE Trans Med Imaging (2012) 2.11
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care (2007) 2.08
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol (2013) 2.07
The concentrative nucleoside transporter family, SLC28. Pflugers Arch (2003) 2.06
Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. J Gastrointest Surg (2015) 2.06
Comparative studies of de novo assembly tools for next-generation sequencing technologies. Bioinformatics (2011) 2.05
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics (2003) 2.03
Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun (2003) 2.01
A completed modeling of local binary pattern operator for texture classification. IEEE Trans Image Process (2010) 2.00
Susceptibility-weighted imaging: the value in cerebral astrocytomas grading. Neurol India (2013) 1.99
Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in smoking prevalence. PLoS One (2010) 1.98
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther (2006) 1.97
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol (2003) 1.97
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev (2007) 1.96
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev (2007) 1.91
Efficient targeted gene disruption in the soma and germ line of the frog Xenopus tropicalis using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2011) 1.90
Activity-dependent development of callosal projections in the somatosensory cortex. J Neurosci (2007) 1.87
Noise reduction for magnetic resonance images via adaptive multiscale products thresholding. IEEE Trans Med Imaging (2003) 1.87
CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev (2002) 1.86
Impact of drug transporter studies on drug discovery and development. Pharmacol Rev (2003) 1.83
Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality. Brain Dev (2005) 1.81
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther (2005) 1.81
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80
Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat Methods (2012) 1.79
4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology (2007) 1.79
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology (2005) 1.79
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther (2002) 1.79
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood (2011) 1.77
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes Dev (2003) 1.76
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol (2006) 1.75